44 related articles for article (PubMed ID: 12533670)
1. Camptothecin poly[n-(2-hydroxypropyl) methacrylamide] copolymers in antitopoisomerase-I tumor therapy: intratumor release and antitumor efficacy.
Zamai M; VandeVen M; Farao M; Gratton E; Ghiglieri A; Castelli MG; Fontana E; D'Argy R; Fiorino A; Pesenti E; Suarato A; Caiolfa VR
Mol Cancer Ther; 2003 Jan; 2(1):29-40. PubMed ID: 12533670
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts.
Tamura K; Takada M; Kawase I; Tada T; Kudoh S; Okishio K; Fukuoka M; Yamaoka N; Fujiwara Y; Yamakido M
Jpn J Cancer Res; 1997 Feb; 88(2):218-23. PubMed ID: 9119752
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic modeling of absorption behavior of 9-aminocamptothecin (9-AC) released from colon-specific HPMA copolymer-9-AC conjugate in rats.
Gao SQ; Sun Y; Kopecková P; Peterson CM; Kopecek J
Pharm Res; 2008 Jan; 25(1):218-26. PubMed ID: 17929146
[TBL] [Abstract][Full Text] [Related]
4. Design and development of pH-responsive alginate-based nanogel carriers for etoposide delivery.
Geyik G; Güncüm E; Işıklan N
Int J Biol Macromol; 2023 Oct; 250():126242. PubMed ID: 37562484
[TBL] [Abstract][Full Text] [Related]
5. Biodegradable Covalently Crosslinked Poly[
Kousalová J; Šálek P; Pavlova E; Konefał R; Kobera L; Brus J; Kočková O; Etrych T
Polymers (Basel); 2024 Jan; 16(2):. PubMed ID: 38257062
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxicity of doxorubicin-conjugated poly[
Plichta Z; Kozak Y; Panchuk R; Sokolova V; Epple M; Kobylinska L; Jendelová P; Horák D
Beilstein J Nanotechnol; 2018; 9():2533-2545. PubMed ID: 30345216
[TBL] [Abstract][Full Text] [Related]
7. Design of pH-responsive antimicrobial peptide melittin analog-camptothecin conjugates for tumor therapy.
Huang S; Gao Y; Ma L; Jia B; Zhao W; Yao Y; Li W; Lin T; Wang R; Song J; Zhang W
Asian J Pharm Sci; 2024 Feb; 19(1):100890. PubMed ID: 38419760
[TBL] [Abstract][Full Text] [Related]
8. A polymer-based ratiometric intracellular glucose sensor.
Zhang L; Su F; Buizer S; Kong X; Lee F; Day K; Tian Y; Meldrum DR
Chem Commun (Camb); 2014 Jul; 50(52):6920-2. PubMed ID: 24840577
[TBL] [Abstract][Full Text] [Related]
9. Anticancer Camptothecin-
Yin Q; Tong R; Yin L; Fan TM; Cheng J
Polym Chem; 2014; 5(5):1581-1585. PubMed ID: 26005498
[TBL] [Abstract][Full Text] [Related]
10. Real-Time Imaging of Protease Action on Substrates Covalently Immobilised to Polymer Supports.
Deere J; McConnell G; Lalaouni A; Maltman BA; Flitsch SL; Halling PJ
Adv Synth Catal; 2007 Jun; 349(8-9):1321-1326. PubMed ID: 19779571
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Potential of the Cyclin-Dependent Kinase Inhibitor Flavopiridol on c-Myc Overexpressing Esophageal Cancer.
Hassan MS; Cwidak N; Johnson C; Däster S; Eppenberger-Castori S; Awasthi N; Li J; Schwarz MA; von Holzen U
Front Pharmacol; 2021; 12():746385. PubMed ID: 34621175
[TBL] [Abstract][Full Text] [Related]
12. Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma.
Hassan MS; Williams F; Awasthi N; Schwarz MA; Schwarz RE; Li J; von Holzen U
Sci Rep; 2019 Nov; 9(1):17608. PubMed ID: 31772236
[TBL] [Abstract][Full Text] [Related]
13. Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma.
Hassan MS; Awasthi N; Li J; Williams F; Schwarz MA; Schwarz RE; von Holzen U
Transl Oncol; 2018 Apr; 11(2):426-435. PubMed ID: 29475139
[TBL] [Abstract][Full Text] [Related]
14. Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib.
Caiola E; Frapolli R; Tomanelli M; Valerio R; Iezzi A; Garassino MC; Broggini M; Marabese M
Sci Rep; 2018 Jan; 8(1):948. PubMed ID: 29343688
[TBL] [Abstract][Full Text] [Related]
15. A novel intraperitoneal metastatic xenograft mouse model for survival outcome assessment of esophageal adenocarcinoma.
Hassan MS; Awasthi N; Li J; Schwarz MA; Schwarz RE; von Holzen U
PLoS One; 2017; 12(2):e0171824. PubMed ID: 28225784
[TBL] [Abstract][Full Text] [Related]
16. Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDX.
Iezzi A; Caiola E; Broggini M
Transl Oncol; 2016 Oct; 9(5):458-465. PubMed ID: 27751351
[TBL] [Abstract][Full Text] [Related]
17. Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells.
Caiola E; Salles D; Frapolli R; Lupi M; Rotella G; Ronchi A; Garassino MC; Mattschas N; Colavecchio S; Broggini M; Wiesmüller L; Marabese M
Oncotarget; 2015 Oct; 6(30):30072-87. PubMed ID: 26353932
[TBL] [Abstract][Full Text] [Related]
18. The Sequence-Specific Cellular Uptake of Spherical Nucleic Acid Nanoparticle Conjugates.
Narayan SP; Choi CH; Hao L; Calabrese CM; Auyeung E; Zhang C; Goor OJ; Mirkin CA
Small; 2015 Sep; 11(33):4173-82. PubMed ID: 26097111
[TBL] [Abstract][Full Text] [Related]
19. Specificity of lectin-immobilized fluorescent nanospheres for colorectal tumors in a mouse model which better resembles the clinical disease.
Kitamura T; Sakuma S; Shimosato M; Higashino H; Masaoka Y; Kataoka M; Yamashita S; Hiwatari K; Kumagai H; Morimoto N; Koike S; Tobita E; Hoffman RM; Gore JC; Pham W
Contrast Media Mol Imaging; 2015; 10(2):135-43. PubMed ID: 24976331
[TBL] [Abstract][Full Text] [Related]
20. A novel preparation method for camptothecin (CPT) loaded folic acid conjugated dextran tumor-targeted nanoparticles.
Zu Y; Wang D; Zhao X; Jiang R; Zhang Q; Zhao D; Li Y; Zu B; Sun Z
Int J Mol Sci; 2011; 12(7):4237-49. PubMed ID: 21845075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
